Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

NCT04365153 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
SARS-CoV 2

Interventions

DRUG: Canakinumab Injection 600mg
DRUG: Canakinumab Injection 300mg
DRUG: Placebos

Sponsor

The Cleveland Clinic

Collaborators

[object Object]